About CARSGEN-B Company

We are a biopharmaceutical company operating in China and the US, focusing on innovative CAR-T cell therapies for the treatment of hematoma and solid tumors. Since we began operations in 2014, we have developed a number of new technologies and globally beneficial product pipelines in-house to address the major challenges facing CAR-T cell therapy, such as improving safety, improving the efficacy of solid tumors, and reducing treatment costs. Our product pipeline includes an upgraded version of the all-human BCMACAR-T, the world's only potentially first-of-its-kind Claudin18.2car-T approved for IND clinical trials, and the world's potential first-of-its-kind GPC3CAR-T. For CAR-T cell therapy, we have received a total of 7 IND approvals in China, the US, and Canada, which is currently the highest number of CAR-T companies in China. Under the leadership of a management team composed of experienced academic experts and industry veterans, we have established an integrated cell therapy platform with in-house capabilities covering target discovery, pilot antibody development, clinical research, and commercial-scale production.